9 results about "PHERETIMA ASPERGILLUM" patented technology

This invention relates to the field of traditional Chinese medicine technology, and more particularly to the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of lung injury. The traditional Chinese medicine composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that this traditional Chinese medicine composition can significantly reduce the level of the inflammatory factor TNF-α, decrease the lung index, and alleviate pathological damage to lung tissue, and can be used for the prevention and treatment of lung injury.

A blood-clearing and lipid-lowering pill is composed of the following ingredients in the indicated weight ratios: Astragalus membranaceus 54-74, Salvia miltiorrhiza 54-74, Paeonia lactiflora 54-74, Carthamus tinctorius 33-53, Pheretima aspergillum 54-74, Hirudo medicinalis 33-53, Crataegus pinnatifida 54-74, Polygonum multiflorum 54-74, Cassia tora 54-74, Gastrodia elata 33-53, Uncaria rhynchophylla 54-74, Eucommia ulmoides 33-53, Achyranthes bidentata 54-74, Os draconis 54-74, Ostrea gigas 54-74, Prunella vulgaris 54-74, and Alisma plantago-aquatica 54-74. This invention can reduce blood viscosity to normal levels in a short period, allowing some patients with vascular stenosis exceeding 75% who require stents to avoid stent grafting, and enabling stroke patients to gradually recover their function.

This invention proposes a traditional Chinese medicine compound for treating ankylosing spondylitis of the kidney-deficiency and damp-heat type accompanied by gastrointestinal dysfunction, along with its preparation method, belonging to the field of traditional Chinese medicine technology. The compound consists of Smilax glabra, Bletilla striata, Paris polyphylla, Geranium wilfordii, Dioscorea hypoglauca, Patrinia scabiosaefolia, Dipsacus asper, Drynaria fortunei, Pyrola rotundifolia, Clematis chinensis, Pheretima aspergillum, Lycopodium clavatum, Corydalis yanhusuo, Paeonia lactiflora, Atractylodes macrocephala (fried), Coix lacryma-jobi (raw), Aucklandia lappa, and Glycyrrhiza uralensis. This invention combines these herbs to achieve a synergistic effect, collectively clearing heat and dampness, strengthening the spleen and kidneys, and unblocking the meridians. The overall formula addresses both strengthening the body's foundation and eliminating pathogenic factors, ensuring unobstructed meridian flow and relieving arthralgia. This compound has the functions of clearing heat and dampness, strengthening the spleen and kidneys, and unblocking the meridians. It offers a short treatment course, rapid efficacy, low recurrence rate after cure, few side effects, and is inexpensive and convenient to use for treating ankylosing spondylitis with gastrointestinal dysfunction.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to a TCM composition, preparation, preparation method, and application for use in the peri-discharge period of acute exacerbations of COPD. The TCM composition comprises the following raw materials: 10-20 parts of *Codonopsis pilosula*, 10-25 parts of *Adenophora stricta*, 15-30 parts of *Clam shell*, 8-15 parts of *Fritillaria thunbergii*, 8-12 parts of *Platycodon grandiflorus*, 8-15 parts of *Paeonia lactiflora*, 8-12 parts of *Aster tataricus*, 8-12 parts of *Lepidium apetalum*, and 8-12 parts of *Pheretima aspergillum*. The TCM preparation derived therefrom can be in the following dosage forms: decoction, paste, tablets, capsules, granules, pills, powders, drop pills, mixtures, or oral liquids. It can be used to prepare drugs that relieve cough, sputum, and shortness of breath, and is suitable for the peri-discharge period of acute exacerbations of COPD.

This invention relates to the application of a traditional Chinese medicine composition in a drug for ulcerative colitis, characterized in that the traditional Chinese medicine composition comprises: 1-100 parts of Magnolia officinalis, 1-100 parts of Areca catechu (roasted), 1-100 parts of Amomum villosum (roasted), 1-100 parts of Ephedra sinica, 1-100 parts of Prunus armeniaca (bitter), 1-100 parts of Notopterygium incisum, 1-100 parts of Zingiber officinale (fresh), 1-100 parts of Pogostemon cablin, 1-100 parts of Eupatorium fortunei, 1-100 parts of Atractylodes lancea, 1-160 parts of Poria cocos, 1-120 parts of Atractylodes macrocephala, 1-100 parts of Gypsum fibrosum, 1-100 parts of Crataegus pinnatifida (roasted), 1-100 parts of Massa fermentata (roasted), 1-100 parts of Hordeum vulgare (roasted), 1-100 parts of Pheretima aspergillum, 1-100 parts of Cynanchum paniculatum, 1-100 parts of Dryopteris crassirhizoma, and 1-100 parts of Lepidium apetalum.

This invention belongs to the field of molecular biology and relates to animal genetics and breeding. It specifically provides genes, primers, applications, and methods for identifying the developmental stages of the clitellum in *Pheretima aspergillum*. Addressing the shortcomings of existing artificial breeding methods for *Pheretima aspergillum*, which rely heavily on visual observation of the clitellum and suffer from significant physiological lag, this invention is the first to discover and screen specific molecular marker genes closely related to the initiation and maturity stages of clitellum differentiation in *Pheretima aspergillum*, and provides highly specific amplification primer sets and detection methods. This invention achieves very early molecular early warning and objective quantitative identification of clitellum development in *Pheretima aspergillum*, providing molecular standards for the quantitative control of nutritional intervention and mating / harvesting timing in artificial breeding. This technology helps to break through the bottleneck of large-scale *Pheretima aspergillum* farming, reduce dependence on wild resources, and is of great significance for protecting ecological red lines and the safety of the traditional Chinese medicine industry.

This invention discloses a combined acupuncture and medication method for treating cervicogenic vertigo, belonging to the field of traditional Chinese medicine clinical treatment technology. The method comprises two parts: oral administration of a specific herbal composition and standardized acupuncture knife therapy. The herbal composition consists of Pinellia ternata, Gastrodia elata, Uncaria rhynchophylla, Poria cocos, Citrus reticulata peel, stir-fried Atractylodes macrocephala, Zingiber officinale, Haliotis diversicolor, Pueraria lobata, Cinnamomum cassia, Corydalis yanhusuo, Ziziphus jujuba, Lycopodium clavatum, Spatholobus suberectus, Pheretima aspergillum, Chaenomeles speciosa, and Paeonia lactiflora in specific dosages, which are then sterilized, preserved, dried, pulverized, and sieved to form capsules for oral administration. The acupuncture knife therapy targets Baihui (GV20), the midpoint of the neck, the left point of the neck, the right point of the neck, and the articular process points. This invention has the effects of resolving phlegm and relieving wind, strengthening the spleen and removing dampness, calming liver yang, relieving exterior cold, and relaxing tendons and vessels, far exceeding the effects of Western medicine treatment alone. It is most effective for the phlegm-dampness obstruction type. It has the advantages of being safe with no side effects, treating both the symptoms and the root cause, having a low recurrence rate, a high degree of standardization, and a wide range of applications. It improves the pathological state of cervicogenic vertigo from the root, embodying the concept of preventive medicine in traditional Chinese medicine, and has significant clinical application value.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of asthma. The TCM composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that the TCM composition provided by this invention can effectively improve airway hyperresponsiveness, reduce lung resistance, and enhance dynamic lung compliance in asthma model animals. Simultaneously, it can significantly reduce the content of pro-inflammatory factors IL-4 and IL-13 in the bronchoalveolar lavage fluid of asthma models, alleviate airway inflammation, and relieve asthma pathological symptoms. It can stably exert its effect in preventing and treating asthma, and its efficacy is stable and its safety is good. It can be further developed into a drug for the prevention and treatment of asthma and has good clinical application prospects.

The invention belongs to the technical field of biological medicine, and particularly relates to earthworm anticoagulant oligopeptide and application thereof. The invention relates to an anticoagulant oligopeptide, which is found by combining the activity-directed separation of pheretima asper (E. Perriver) with the screening of an AI (artificial intelligence) prediction model. The amino acid sequence of the oligopeptide is LMWFSDRNK; the oligopeptide regulates thrombin in an allosteric manner, enhances the combination of thrombin and antithrombin, and can effectively inhibit blood coagulation and thrombus formation at in-vivo and in-vitro levels; the oligopeptide has a remarkable anticoagulant effect and is suitable for research and development of antithrombotic drugs.